Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.

Broutin S, Ameur N, Lacroix L, Robert T, Petit B, Oumata N, Talbot M, Caillou B, Schlumberger M, Dupuy C, Bidart JM.

Clin Cancer Res. 2011 Apr 1;17(7):2044-54. doi: 10.1158/1078-0432.CCR-10-2041. Epub 2011 Feb 15.

2.

Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.

Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C.

J Clin Endocrinol Metab. 2014 Feb;99(2):498-509. doi: 10.1210/jc.2013-2574. Epub 2013 Nov 25.

PMID:
24276455
3.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

PMID:
15240784
4.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM.

Thyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17.

5.

Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.

Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F.

Biochem Pharmacol. 2006 Aug 14;72(4):405-14. Epub 2006 Jun 6.

PMID:
16756963
6.

A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.

Johanson V, Ahlman H, Bernhardt P, Jansson S, Kölby L, Persson F, Stenman G, Swärd C, Wängberg B, Stridsberg M, Nilsson O.

Endocr Relat Cancer. 2007 Jun;14(2):433-44.

7.

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A.

J Endocrinol Invest. 2012 Feb;35(2):181-90. doi: 10.3275/7609. Epub 2011 Mar 21.

PMID:
21422803
8.

Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.

Koga K, Hattori Y, Komori M, Narishima R, Yamasaki M, Hakoshima M, Fukui T, Maitani Y.

Cancer Sci. 2010 Apr;101(4):941-7. doi: 10.1111/j.1349-7006.2009.01484.x.

9.

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.

De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.

PMID:
23526464
10.

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.

Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.

J Clin Endocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012 Mar 22.

PMID:
22442268
11.

The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.

Kushchayeva Y, Jensen K, Recupero A, Costello J, Patel A, Klubo-Gwiezdzinska J, Boyle L, Burman K, Vasko V.

J Clin Endocrinol Metab. 2014 May;99(5):E734-45. doi: 10.1210/jc.2013-3369. Epub 2014 Jan 31.

PMID:
24483157
12.

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26.

13.

Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity.

Zhu W, Hai T, Ye L, Cote GJ.

J Clin Endocrinol Metab. 2010 Jan;95(1):439-44. doi: 10.1210/jc.2009-1485. Epub 2009 Nov 6.

14.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.

J Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.

15.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
16.

A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.

Bugalho MJ, Domingues R, Borges A.

Oncologist. 2009 Nov;14(11):1083-7. doi: 10.1634/theoncologist.2009-0195. Epub 2009 Nov 3.

17.

Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.

Gorla L, Mondellini P, Cuccuru G, Miccichè F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C, Bongarzone I.

Mol Carcinog. 2009 Mar;48(3):220-31. doi: 10.1002/mc.20474.

PMID:
18756447
18.

Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.

Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M.

Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.

PMID:
18791128
19.

Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.

Bousquet G, Varna M, Ferreira I, Wang L, Mongiat-Artus P, Leboeuf C, de Bazelaire C, Faivre S, Bertheau P, Raymond E, Germain S, Janin A.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1183-93. doi: 10.1007/s00280-013-2300-0. Epub 2013 Sep 24.

PMID:
24061866
20.

Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

Drosten M, Stiewe T, Pützer BM.

Hum Gene Ther. 2003 Jul 1;14(10):971-82.

PMID:
12869215

Supplemental Content

Support Center